Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Abivax Announces Full Exercise of Underwriters Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (637.5M)
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing…
